CA
PHAT icon

Cliff Asness’s Phathom Pharmaceuticals PHAT Stock Holding History

Cliff Asness’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
134,901
+79,433
+143% +$906K ﹤0.01% 2810
2026
Q1 		$616K Buy
55,468
+1,020
+2% +$12.9K ﹤0.01% 3016
2025
Q4 		$903K Buy
54,448
+1,819
+3% +$26K ﹤0.01% 2613
2025
Q3 		$619K Buy
52,629
+2,705
+5% +$27.9K ﹤0.01% 2701
2025
Q2 		$479K Sell
49,924
-57,475
-54% -$318K ﹤0.01% 2634
2025
Q1 		$673K Buy
107,399
+89,741
+508% +$545K ﹤0.01% 2253
2024
Q4 		$143K Buy
+17,658
New +$219K ﹤0.01% 2722
2024
Q1 		– Sell
-18,427
Closed -$168K – 2481
2023
Q4 		$168K Sell
18,427
-4,408
-19% -$38K ﹤0.01% 2237
2023
Q3 		$237K Buy
+22,835
New +$313K ﹤0.01% 2089
2023
Q1 		– Sell
-10,046
Closed -$113K – 2233
2022
Q4 		$113K Buy
+10,046
New +$104K ﹤0.01% 2131

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Cliff Asness's PHAT Position: Q2 2026 in Review

Cliff Asness increased its Phathom Pharmaceuticals (PHAT) stake by 143% in Q2 2026, buying an estimated $906K and bringing the position to 134,901 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2810.

Cliff Asness first reported a position in PHAT in Q4 2022 and has held it in 10 quarters since. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Cliff Asness held 134,901 shares of Phathom Pharmaceuticals worth $1.46M as of Q2 2026.
  • Cliff Asness bought 79,433 Phathom Pharmaceuticals shares in Q2 2026, an estimated $906K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2810 holding.
  • Cliff Asness first reported a position in Phathom Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.